Emerging therapeutic targets in schwannomas and meningiomas: The neurofibromatosis Type 2 protein

Expert Opinion on Therapeutic Targets

Volumn 3, Issue 2, 1999, Pages 335-364

  Nakao, Mitsuyoshi ^a   Kimura, Yoriyoshi ^a   Saya, Hideyuki ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0003282596     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.3.2.335     Document Type: Review

References (59)

1. LUTCHMAN M, ROULEAU GA: Neurofibromatosis Type 2: a new mechanism of tumor suppression. Trends Neurosci. (1996) 19:373-377. (Pubitemid 26270512)
2. ELDRIDGE R: Central neurofibromatosis with bilateral acoustic neurinoma. Adv. Neurol. (1981) 29:57-65.
3. GUSELLA JF, RAMESH V, MacCOLLIN M, JACOBY LB: Neurofibromatosis Type 2: loss of merlin's protective spell. Curr. Opin. Genet. Develop. (1996) 6:87-92. (Pubitemid 26059057)
4. MARTUZA RL, ELDRIDGE R: Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). New Engl. J. Med. (1988) 318:684-688.
5. ROULEAU GA, MEREL P, LUTCHMAN M et al.: Alteration in a new gene encoding a putative membraneorganizing protein causes neurofibromatosis Type 2. Nature (1993) 363:515-521. (Pubitemid 23186636)
6. TROFATTER JA, MacCOLLIN M, RUTTER JL et al.: A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell (1993) 72:791-800. (Pubitemid 23093886)
7. KIMURA Y, KOGA H, ARAKI N et al.: The involvement of calpain-dependent proteolysis of the tumor suppressor NF2 (merlin) in schwannomas and meningiomas. Nature Med. (1998) 4:915-922. (Pubitemid 28364030)
8. RAGGE NK, BASER ME, KLEIN J et al.: Ocular abnormalities in neurofibromatosis 2. Am. J. Ophthal. (1995) 120:634-641.
9. EVANS DGR, HUSON SM, DONNAI D et al. : A clinical study of Type 2 neurofibromatosis. Quart. J. Med. (1992) 84:603-618. (Pubitemid 23007763)
10. GUTMANN D, AYLSWORTH A, CARLEY J et al.: The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA (1997) 278:51-57. (Pubitemid 27274517)
11. SEIZINGER BR, ROULEAU G, OZELIUS LJ et al.: Common pathogenetic mechanism for three tumor types in bilateral acoustic neurofibromatosis. Science (1987) 236:317-319. (Pubitemid 17061050)
12. WERTELECKI W, ROULEAU GA, SUPERNEAU DW et al.: Neurofibromatosis 2: clinical and DNA linkage studies of a large kindred. New Engl. J. Med. (1988) 319:278-283.
13. TSUKITA S, YONEMURA S: ERM (ezrin/radixin/moesin) family: from cytoskeleton to signal transduction. Curr. Opin. Cell Biol. (1997) 9:70-75. (Pubitemid 27065111)
14. ALGRAIN M, TURUNEN O, VAHERI A et al.: Ezrin contains cytoskeleton and membrane binding domains accounting for its proposed role as a membranecytoskeletal linker. J. Cell. Biol. (1993) 120:129-139.
15. SCOLES DR, HUYNH DP, MORCOS PA et al.: Neurofibromatosis 2 tumor suppressor schwannomin interacts with bII-spectrin. Nature Genet. (1998) 18:354-359. (Pubitemid 28158164)
16. GONZALEZ-AGOSTI C, XU L, PINNEY D et al.: The merlin tumor suppressor localizes preferentially in membrane ruffles. Oncogene (1996) 13:1239-1247. (Pubitemid 26343577)
17. PELTON PD, SHERMAN LS, RIZVI TA et al.: Ruffling membrane, stress fiber, cell spreading and proliferation abnormalities in human Schwannoma cells. Oncogene (1998) 17:2195-2209. (Pubitemid 28515373)
18. McCLATCHEY AI, SAOTOME I, RAMESH V et al.: The NF2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev. (1997) 11:1253-1265. (Pubitemid 27235358)
19. McCLATCHEY AI, SAOTOME I, MERCER K et al.: Mice heterozygous for a mutation at the NF2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. (1998) 12:1121-1133. (Pubitemid 28194048)
20. EVANS DGR, HUSON SM, DONNAI D et al.: A genetic study of Type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. J. Med. Genet. (1992) 29:841-846. (Pubitemid 23035205)
21. KOGA H, ARAKI N, TAKESHIMA H et al.: Impairment of cell adhesion by expression of the mutant neurofibromatosis Type 2 (NF2) genes which miss exons in the ERM-homology domain. Oncogene (1998) 17:801-810. (Pubitemid 28430202)
22. RUTTLEDGE MH, ANDERMANN AA, PHELAN CM et al.: Type of mutations in the neurofibromatosis Type 2 gene (NF2) frequently determines severity of disease. Am. J. Hum. Genet. (1994) 54:1022-1029.
23. RUTTLEDGE MH, SARRAZIN J, RANGARATNAM S et al.: Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nature Genet. (1994) 6:180-184. (Pubitemid 24188600)
24. MEREL P, HOANG-XUAN K, SANSON M et al.: Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosom. Cancer (1995) 13:211-216.
25. BIJLSMA EK, BROUWER MR, BOSCH DA et al.: Molecular characterization of chromosome 22 deletions in schwannomas. Genes Chromosom. Cancer (1992) 5:201-205.
26. TWIST EC, RUTTLEDGE MH, ROUSSEAU M et al.: The neurofibromatosis Type 2 gene is inactivated in schwannomas. Hum. Mol. Genet. (1994) 3:147-151. (Pubitemid 24038157)
27. ARAKAWA H, HAYASHI N, NAGASE H et al.: Alternative splicing of the NF2 gene and its mutation analysis of breast and colorectal cancers. Hum. Mol. Genet. (1994) 3:565-568. (Pubitemid 24122167)
28. BIANCHI AB, HARA T, RAMESH V et al.: Mutations in transcripts isoforms of the neurofibromatosis Type 2 gene in multiple human tumour types. Nature Genet. (1994) 6:185-192. (Pubitemid 24188601)
29. BIANCHI AB, MITSUNAGA SI, CHENG JQ et al.: High frequency of inactivating mutations in the neurofibromatosis Type 2 gene (NF2) in primary malignant mesotheliomas. Proc. Natl. Acad. Sci. USA (1995) 92:10854-10858.
30. MacCOLLIN M, RAMESH V, JACOBY LB et al.: Mutational analysis of patients with neurofibromatosis 2. Am. J. Hum. Genet. (1994) 55:314-320. (Pubitemid 24233215)
31. TAKESHIMA H, IZAWA I, LEE PSY et al.: Detection of cellular proteins that interact with the NF2 tumor suppressor gene product. Oncogene (1994) 9:2135-2144. (Pubitemid 24228661)
32. STEMMER-RACHAMIMOV OA, INO Y, LIM ZY et al.: Universal absence of merlin, but not other ERM family members, in schwannomas. Am. J. Pathol. (1997) 151:1649-1654.
33. GUTMANN DH, GIORDANO MJ, FISHBACK AS, GUHA A: Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology (1997) 49:267-270. (Pubitemid 27328718)
34. LEE JH, SUNDARAM V, STEIN DJ et al.: Reduced expression of schwannomin/merlin in human sporadic meningiomas. Neurosurgery (1997) 40:578-587. (Pubitemid 27108132)
35. SAIDO TC, SORIMACHI H, SUZUKI K: Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J. (1994) 8:814-822.
36. SUZUKI K, SORIMACHI H, YOSHIZAWA T et al.: Calpain: novel family members, activation, and physiologic function. Biol. Chem. Hoppe-Seyler (1995) 376:523-529.
37. SORIMACHI H, ISHIURA S, SUZUKI K: Structure and physiological function of calpains. Biochem. J. (1997) 328:721-732. (Pubitemid 28005767)
38. TSUBUKI S, SAITO Y, TOMIOKA M: Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J. Biochem. (1996) 119:572-576. (Pubitemid 26100945)
39. COUX O, TANAKA K, GOLDBERG AL: Structure and functions of the 20S and 26S proteasomes. Annu. Rev. Biochem. (1996) 65:801-847. (Pubitemid 26255262)
40. BURKHART WA, MOYER MB, BAILEY JM, MILLER CG: Electroblotting of proteins to Teflon tape and membranes for N-And C-terminal sequence analysis. Anal. Biochem. (1996) 236:364-367.
41. DU X, SAIDO TC, TSUBUKI S et al.: Calpain cleavage of the cytoplasmic domain of the integrin beta 3 subunit. J. Biol. Chem. (1995) 270:26146-26151.
42. SIMAN R, BAUDRY M, LYNCH G: Brain fodrin: substrate for calpain I, an endogenous calcium-Activated protease. Proc. Natl. Acad. Sci. USA (1984) 81:3572-3576. (Pubitemid 14122716)
43. YANG LS, KSIEZAK RH: Calpain-induced proteolysis of normal human tau and tau associated with paired helical filaments. Eur. J. Biochem. (1995) 233:9-17.
44. INOMATA M, HAYASHI M, OHNO-IWASHITA Y et al.: Involvement of calpain in integrin-mediated signal transduction. Arch. Biochem. Biophys. (1996) 328:129-134. (Pubitemid 26108178)
45. SELLIAH N, BROOKS WH, ROSZMAN TL: Proteolytic cleavage of alpha-Actinin by calpain in T cells stimulated with anti-CD3 monoclonal antibody. J. Immunol. (1996) 156:3215-3221. (Pubitemid 26123535)
46. JAY D, STRACHER A: Expression in Escherichia coli, phosphorylation with cAMP-dependent protein kinase and proteolysis by calpain of a 71-kDa domain of human endothelial actin binding protein. Biochem. Biophys. Res. Commun. (1997) 232:555-558. (Pubitemid 27216259)
47. HUANG C, TANDON NN, GRECO NJ et al.: Proteolysis of platelet cortactin by calpain. J. Biol. Chem. (1997) 272:19248-19252. (Pubitemid 27337715)
48. ELVIRA M, DIEZ JA, WANG KK, VILLALOBO A: Phosphorylation of connexin-32 by protein kinase C prevents its proteolysis by m-calpain and m-calpain. J. Biol. Chem. (1993) 268:14294-14300. (Pubitemid 23195555)
49. LITERSKY JM, JOHNSON GV: Phosphorylation by cAMP-dependent protein kinase inhibits the degradation of tau by calpain. J. Biol. Chem. (1992) 267:1563-1568.
50. GREENWOOD JA, TRONCOSO JC, COSTELLO AC, JOHNSON GV: Phosphorylation modulates calpainmediated proteolysis and calmodulin binding of the 200-kDa and 160-kDa neurofilament proteins. J. Neurochem. (1993) 61:191-199. (Pubitemid 23175901)
51. NAGAO S, SAIDO TC, AKITA Y et al.: Calpain-calpastatin interactions in epidermoid carcinoma KB cells. J. Biochem. (1994) 115:1178-1184. (Pubitemid 24191336)
52. BILLGER M, WALLIN M, KARLSSON JO: Proteolysis of tubulin and microtubule-Associated proteins 1 and 2 by calpain I and II. Difference in sensitivity of assembled and disassembled microtubules. Cell Calcium (1988) 9:33-44. (Pubitemid 18070339)
53. SAIDO TC, NAGAO S, SHIRAMINE M et al.: Autolytic transition of m-calpain upon activation as resolved by antibodies distinguishing between the pre-And post-Autolysis forms. J. Biochem. (1992) 111:81-86.
54. SCHEFFNER M, HUIBREGTSE JM, VIERSTRA RD, HOWLEY PM: The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell (1993) 75:495-505. (Pubitemid 23335075)
55. CATZAVELOS C, BHATTACHARYA N, UNG YC et al.: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nature Med. (1997) 3:227-230. (Pubitemid 27064710)
56. LODA M, KUCOR B, TAM SW et al.: Increased proteasome-dependent degradation of the cyclindependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med. (1997) 3:231-234. (Pubitemid 27064711)
57. PITTS LH, JACKLER RK: Treatment of acoustic neuromas. New Engl. J. Med. (1998) 339:1471-1473. (Pubitemid 28516073)
58. JENSEN RL, ORIGITANO TC, LEE YS et al.: In vitro growth inhibition of growth factor-stimulated meningioma cells by calcium channel antagonists. Neurosurgery (1995) 36:365-373.
59. JENSEN RL, LEE YS, GUIJRATI M et al.: Inhibition of in vitro meningioma proliferation after growth factor stimulation by calcium channel antagonists: Part II-Additional growth factors, growth factor receptor immunohistochemistry, and intracellular calcium measurements. Neurosurgery (1995) 37:937-946.